Information from the new technology would have been too confusing for consumers, CEO says.

Gene sequencing startup 23andme has abandoned plans to develop a next generation sequencing technology, CEO Anne Wojcicki said on Wednesday.

The company currently offers consumers information about their genetic heritage via a $200 mail-in DNA testing kit and a more limited $100 ancestry report. The company was valued at over $1 billion in a fund raising round last year, pushing it into the category of so-called unicorns.

Wojcicki had been working on developing a new technology that could extract much more information at rapid speeds and give more precise reports and advice to consumers. The problem was that 23andme is focused on giving information directly to consumers, not to their doctors, and the next gen information might have been too complex or too vague to fit that model, she said.

Source: Why 23andme Killed Its Next Generation Gene Sequencing Project

Categories: Uncategorized

Related Posts


Cancer Gene Trust Search

Source: Cancer Gene Trust Search Related PostsScientists Find Form of Crispr Gene Editing With New Capabilities – The New York TimesPills of Science – 1 WeekDNA Extraction Virtual LabDNA Extraction Virtual LabCancer Gene Panels


The Long-Term Stock Exchange Is Worth a Shot – Bloomberg

Silicon Valley venture capitalists are shaking things up with “tenure voting.” Source: The Long-Term Stock Exchange Is Worth a Shot – Bloomberg Related PostsThe Right Way to Grant Equity to Your EmployeesHow CEO Anne Wojcicki Read more…


How to Be a Know-It-All | The New Yorker

What you learn from the Very Short Introduction series. Source: How to Be a Know-It-All | The New Yorker Related PostsIntroduction to Scientific Python – StanfordDeep LearningIntroduction to Biostatistics and BioinformaticsIntroduction to Biostatistics and BioinformaticsThe Read more…